Investors

 

2014

December 19, 2014
Flamel Technologies announces Second Clinical Trial with Micropump Sodium Oxybate

December 16, 2014
Flamel Technologies Transfers Intangible Property to Irish-Based Subsidiary in Global Reorganization

December 15, 2014
Flamel Technologies to Be Included in NASDAQ Biotech Index

December 01, 2014
Flamel Technologies Closes Sale of Development and Manufacturing Facility in Pessac, France to Recipharm AB

November 28, 2014
Flamel Technologies Sells Development and Manufacturing Facility in Pessac, France to Recipharm AB

October 31, 2014
Flamel Technologies Announces Third Quarter Results of Fiscal Year 2014

October 21, 2014
Flamel Technologies to Report Third Quarter of Fiscal Year 2014 Results

September 29, 2014
Flamel Technologies Announces Positive Results of First-in-Man Clinical Trial With LiquiTime(R) Ibuprofen

September 11, 2014
Flamel Technologies Announces Plan to Appoint New VP of R&D

August 4, 2014
Flamel Notified of FDA Communication to Unapproved Manufacturers of Neostigmine Methylsulfate

July 29, 2014
Flamel Technologies Announces Second Quarter of Fiscal Year 2014 Results

July 22, 2014
Flamel Technologies to Report Second Quarter of Fiscal Year 2014 Results

July 02, 2014
Flamel Technologies Announces Results of 2014 Annual Meeting

June 25, 2014
Flamel Technologies Announces Positive Preclinical Results For Its Once-A-Week Formulation of Exenatide

June 16, 2014
Flamel Technologies Receives Class 1 Response Designation for Second NDA

June 05, 2014
Flamel Technologies Announces Intent to Resubmit Second NDA

May 12, 2014
Flamel Technologies Announces First Quarter of Fiscal Year 2014 Results

May 02, 2014
Flamel Technologies to Report First Quarter of Fiscal Year 2014 Results

April 29, 2014
Flamel Technologies Announces Receipt of Complete Response Letter From FDA Citing Issues at the Facility of the Supplier of the Active Ingredient

April 07, 2014
Flamel Technologies Announces Positive Results of a First-in-Man Clinical Trial With Micropump Sodium Oxybate

March 25, 2014
Flamel Technologies Announces Fourth Quarter and Full Year 2013 Results

March 17, 2014
Flamel Technologies to Report Fourth Quarter and Fiscal Year 2013 Results and Conference Call

March 07, 2014
Flamel Technologies Announces Pricing of Public Offering of American Depositary Shares

March 06, 2014
Flamel Technologies Announces Proposed Underwritten Public Offering of American Depositary Shares

back to the top

2013

December 04, 2013
Flamel Technologies Announces $15 Million Line of Credit

October 31, 2013
Flamel Technologies Announces Third Quarter 2013 Results

October 17, 2013
Flamel Technologies Announces Projected Release Date of Third Quarter 2013 Results and Conference Call

September 11, 2013
Flamel Technologies Announces Acceptance of FDA Review for Second NDA

July 29, 2013
Flamel Technologies Announces Second Quarter 2013 Results

July 22, 2013
Flamel Technologies Announces Projected Release Date of Second Quarter 2013 Results and Conference Call

July 01, 2013
Flamel Technologies Announces Resubmission of Second NDA

June 24, 2013
Flamel Technologies Announces Results of 2013 Annual Meeting

June 06, 2013
Flamel Technologies Announces Product Partnership Agreement

May 23, 2013
Flamel Technologies Obtains Rights to Two Molecules of Trigger Lock Product Line

May 07, 2013
Flamel Technologies Announces First Quarter 2013 Results

April 23, 2013
Flamel Technologies Announces Projected Release Date of First Quarter 2013 Results and Conference Call

March 22, 2013
Judge Dismisses 2007 Class Action Case Against Flamel Technologies

February 28, 2013
Flamel Technologies Announces Fourth Quarter and Full Year 2012 Results

February 22, 2013
Flamel Technologies Announces Projected Release Date of Fourth Quarter 2012 Results and Conference Call

February 07, 2013
Flamel Technologies Announces $15 Million Debt Financing to Advance R&D Efforts

back to the top

2012

November 05, 2012
Flamel Technologies Announces Third Quarter 2012 Results and Other Updates

October 30, 2012
Flamel Technologies Announces Projected Release Date of Third Quarter 2012 Results and Conference Call

October 18, 2012
Flamel Technologies Announces FDA Acceptance of New Drug Application

July 25, 2012
Flamel Technologies Announces Second Quarter 2012 Results

July 23, 2012
Flamel Technologies Announces Projected Release Date of Second Quarter 2012 Results and Conference Call

June 25, 2012
Flamel Technologies Medusa-Formulated Interferon-Alpha Demonstrates Favorable Antiviral Activity and Safety in a Phase 2 Clinical Study

June 25, 2012
Flamel Technologies Announces Results of Annual Meeting and Election of Stephen H. Willard Chairman

May 07, 2012
Flamel Technologies Announces First Quarter 2012 Results

April 30, 2012
Flamel Technologies Announces Projected Release Date of First Quarter 2012 Results and Conference Call

March 14, 2012
Flamel Technologies Announces Acquisition of Eclat Pharmaceuticals

March 14, 2012
Flamel Technologies Announces Fourth Quarter And Year-End 2011 Results

March 13, 2012
Flamel Technologies Announces Projected Release Date of Fourth Quarter and Year-End 2011 Results; Additional Releases; Conference Call

back to the top